Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.
about
Antibiotic strategies in the era of multidrug resistanceCritical evaluation of ceftolozane-tazobactam for complicated urinary tract and intra-abdominal infectionsEmpiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing EnterobacteriaceaeManagement of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.ESBL Detection: Comparison of a Commercially Available Chromogenic Test for Third Generation Cephalosporine Resistance and Automated Susceptibility Testing in EnterobactericeaeKlebsiella pneumoniae bloodstream infection: epidemiology and impact of inappropriate empirical therapy.Cefepime Therapy for Monomicrobial Enterobacter cloacae Bacteremia: Unfavorable Outcomes in Patients Infected by Cefepime-Susceptible Dose-Dependent Isolates.Impact of appropriateness of empiric therapy on outcomes in community-onset bacteremia by extended-spectrum-β-lactamase producing Escherichia coli and Klebisella pneumoniae definitively treated with carbapenems.Strategies to reduce curative antibiotic therapy in intensive care units (adult and paediatric).Recent Updates on the Role of Pharmacokinetics-pharmacodynamics in Antimicrobial Susceptibility Testing as Applied to Clinical Practice.Comparison Between Carbapenems and β-Lactam/β-Lactamase Inhibitors in the Treatment for Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: A Systematic Review and Meta-Analysis.Integrating forecast probabilities in antibiograms: a way to guide antimicrobial prescriptions more reliably?Use of β-Lactam/β-Lactamase Inhibitors for Extended-Spectrum-β-Lactamase Infections: Defining the Right Patient Population.Impact of CLSI Breakpoint Changes on Microbiology Laboratories and Antimicrobial Stewardship ProgramsStructure and Functional Characterisation of a Distinctive β-Lactamase from an Environmental Strain EMB20 of Bacillus cereus.WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015.Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014.Biliary diseases as main causes of pyogenic liver abscess caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae.What does the susceptible-dose dependent interpretive category for cefepime in ESBL-producing bacteria?Incidence of extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates that test susceptible to cephalosporins and aztreonam by the revised CLSI breakpoints.Cefepime-induced neurotoxicity: a systematic review.Making sense of cephalosporin and amoxicillin/clavulanate susceptibility testing for uropathogens.Point-Counterpoint: Piperacillin-tazobactam should be used to treat infections with ESBL-positive organisms.The Role of Cefepime in the Treatment of Extended-Spectrum Beta-Lactamase Infections.Pharmacokinetic/pharmacodynamic parameters for treatment optimization of infection due to antibiotic resistant bacteria: a summary for practical purposes in children and adults.Response to Treatment of spontaneous bacterial peritonitis: beyond the current international guidelines.Amperometric detection of extended-spectrum β-lactamase activity: application to the characterization of resistant E. coli strains.Clinical Outcomes of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Infections with Susceptibilities among Levofloxacin, Cefepime, and Carbapenems.Characterization of the Clinical Outcomes With Cefepime in a Neonatal Intensive Care Unit: A Retrospective Cohort Study.
P2860
Q26744091-FBD2B163-F8A9-4688-9EB3-55A23EA40FE9Q26747429-D9010F30-4986-41A9-BF60-6D1AED450C45Q28551534-98CB7E37-D588-4A90-B56C-B6A7BF9A9468Q36078359-E983D8DC-9659-4B5A-836B-DF750EA43145Q36095794-7F63E074-D291-4292-997E-63F735C487D1Q36150730-18D5CD77-3898-46FD-ADB7-10E7DB953F43Q36290474-EFDCE283-F9EC-4D43-AF11-120F7474D735Q38401630-C135D403-F142-496F-9B66-CCEE60C7CE4AQ38528292-DE101014-B147-4BC7-8096-6C15BFBFE14FQ38536299-03ABE4BD-87EA-48C1-BEC7-73B12218324BQ38681779-5EC7DDD0-3281-4B54-801C-09BF0478279DQ39147849-A1CFEAE3-75A1-4584-A82D-91FB22BF4866Q39353134-40A43640-A8CE-49F5-A721-CCA1A825E7EBQ39577254-96AC42C1-0454-4C9E-A870-73B6EE1B507CQ40152739-C493B9F2-DED3-4EDD-956B-B8135464120FQ40281991-5E4F5EA5-88E8-4B98-95BF-0D5731F9EB79Q40315393-7C2EB881-9617-4EF0-9B40-56E80EE62247Q40352823-7A280316-ABCC-4BD2-B935-EBF3209F5869Q40479700-63DBCEF6-8900-48A3-A7BC-BB51192F7AD9Q40714813-1CD06728-2D77-4D7C-86DA-9C19F161BFF1Q41779878-AA900D78-1B95-4A82-B331-FF25757349F8Q43915417-5F87979B-0CCD-4EC8-BBB7-58479FA97556Q46355688-8C760AE8-FF98-423D-857E-7E7626431305Q47315442-F072FF57-7230-4BBC-BEB8-5C4372A69BA7Q47427370-B47E9DC0-9495-4D7E-BC2A-6947E8E7A2E4Q48197188-421E8B93-F1A7-4FE9-A8AC-B9BA1449157EQ48806317-C3EB9887-5212-4F2B-8AD9-C5E191853780Q53552462-9752337F-9D16-4E40-B699-0D362CB53255Q53693902-44B0E92D-A2C2-4186-8E1E-4017C2A64540Q55404164-06E0EFDF-F505-4547-9B47-19F065C71921
P2860
Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Determining a clinical framewo ...... -producing Enterobacteriaceae.
@en
type
label
Determining a clinical framewo ...... -producing Enterobacteriaceae.
@en
prefLabel
Determining a clinical framewo ...... -producing Enterobacteriaceae.
@en
P2093
P2860
P356
P1476
Determining a clinical framewo ...... -producing Enterobacteriaceae.
@en
P2093
Christopher J Graber
Hien M Nguyen
Kileen L Shier
P2860
P304
P356
10.1093/JAC/DKT450
P407
P577
2013-11-20T00:00:00Z